Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDJ001 in moderate-to-severe active rheumatoid arthritis
NCT05957107Phase 2Completed
- Sponsor
- Beijing VDJBio Co., Ltd.
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of VDJ-001 in rheumatoid arthritis (RA), sponsored by Beijing VDJBio Co., Ltd.. Started May 2022; status: completed.
02
Drugs
VDJ-001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05957107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957107.